The FDA has approved Zurnai (Purdue Pharma), the first nalmefene hydrochloride auto-injector for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. The agency approved the first nasal spray formulation of nalmefene in May 2023.
Drug overdose persists as a major public health issue in the United States, with more than 107,000 reported fatal overdoses occurring in 2023, primarily driven by synthetic opioids like illicit